MedTrace Logo

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

NCT06792149 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-01-24

No results posted yet for this study

Summary

The therapeutic regimens for adjuvant and neoadjuvant chemotherapy in gastric cancer (GC) predominantly hinge on clinical experience. Consequently, there is an imperative need for preclinical models to facilitate the guidance of individualized medicine. The investigators plan to establish three-dimensional (3D) bioprinted GC models derived from surgically resected tumor tissues of GC patients. These in vitro 3D models will be subjected to treatment with the identical chemotherapy drugs administered to the corresponding patients from whom the models are sourced. The sensitivity of the chemotherapy drugs will be assayed within the in vitro models, and the actual response to chemotherapy in patients will be meticulously evaluated. This observational study aims to substantiate the potential utility of 3D bioprinted tumor models in prognosticating the response to chemotherapy in GC.

Conditions

  • STOMACH NEOPLASM

Interventions

PROCEDURE

surgical resection

Surgical resection will be performed for locoregional lesions .

OTHER

Adjuvant chemotherapy

Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

OTHER

neoadjuvant therapy

Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792149 on ClinicalTrials.gov